SummaryAlprazolam is an agonist at the GABAA receptor, a key player in the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) pathway. With the ability to enhance the effects of GABA in the brain, alprazolam unleashes a wave of anxiolytic, sedative, and anticonvulsant properties. Alprazolam has also been found to have some efficacy in treating epilepsy and asthma-related anxiety. The FDA approved this drug on October 16, 1981, and it was developed by none other than Takeda Pharmaceutical, a leading Japanese pharmaceutical company. Alprazolam comes in various forms, including immediate-release and extended-release tablets, as well as oral solutions. However, caution must be exercised while using this drug, as it may lead to dependence and withdrawal symptoms. The benefits of alprazolam are undeniable, but it's essential to use it with care. |
Drug Type Small molecule drug |
Synonyms 8-Chloro-1-methyl-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine, Alprazolcem, AP-1002 + [16] |
Target |
Mechanism DOCK5 inhibitors(dedicator of cytokinesis 5 inhibitors), GABAA receptor agonists(Gamma-aminobutyric acid A receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (16 Oct 1981), |
RegulationBreakthrough Therapy (CN) |
Molecular FormulaC17H13ClN4 |
InChIKeyVREFGVBLTWBCJP-UHFFFAOYSA-N |
CAS Registry28981-97-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00225 | Alprazolam |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Anxiety | JP | Teva Takeda Pharma Ltd.Startup | 15 Feb 1984 |
Anxiety | JP | 15 Feb 1984 | |
Catatonia | JP | Teva Takeda Pharma Ltd.Startup | 15 Feb 1984 |
Depressive Disorder | JP | 15 Feb 1984 | |
Depressive Disorder | JP | Teva Takeda Pharma Ltd.Startup | 15 Feb 1984 |
Sleep Initiation and Maintenance Disorders | JP | Teva Takeda Pharma Ltd.Startup | 15 Feb 1984 |
Sleep Initiation and Maintenance Disorders | JP | 15 Feb 1984 | |
Anxiety Disorders | US | 16 Oct 1981 | |
Anxiety Disorders | US | 16 Oct 1981 | |
Panic Disorder | US | 16 Oct 1981 | |
Panic Disorder | US | 16 Oct 1981 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Status Epilepticus | Phase 3 | US | 07 Dec 2021 | |
Status Epilepticus | Phase 3 | CN | 07 Dec 2021 | |
Status Epilepticus | Phase 3 | JP | 07 Dec 2021 | |
Status Epilepticus | Phase 3 | AU | 07 Dec 2021 | |
Status Epilepticus | Phase 3 | BG | 07 Dec 2021 | |
Status Epilepticus | Phase 3 | CZ | 07 Dec 2021 | |
Status Epilepticus | Phase 3 | FR | 07 Dec 2021 | |
Status Epilepticus | Phase 3 | DE | 07 Dec 2021 | |
Status Epilepticus | Phase 3 | HU | 07 Dec 2021 | |
Status Epilepticus | Phase 3 | IT | 07 Dec 2021 |
Phase 1 | - | 13 | Placebo (Lactose) Capsule+Cannabis (0%/ THC / 0% CBD) ("Sober" or Double Placebo) | lzgkzjdpmd(kampxxugve) = kqcpwswnyj ywzvihlheg (iowlluyxvx, bpxlufhqgi - oirznmcppd) View more | - | 25 Jul 2023 | |
Cannabis (0%/ THC / 0% CBD)+0.75 mg Alprazolam Capsule (Active Alprazolam (Xanax), Placebo Cannabis) | lzgkzjdpmd(kampxxugve) = rwxntvtlnv ywzvihlheg (iowlluyxvx, doibtehicl - tmlsrvmyud) View more | ||||||
Phase 2 | 116 | yqiyzridgg(klibiltlar) = ucgfksfkbs oslzmkvbjy (ffezutomho ) | - | 21 Oct 2022 | |||
yqiyzridgg(klibiltlar) = fjsglydcwq oslzmkvbjy (ffezutomho ) | |||||||
Phase 2 | 8 | dgcycpxnzb(ljintlnfmq) = no adverse events were serious or severe kzdrdipmcs (glildqogqc ) | Positive | 09 Apr 2019 | |||
Phase 4 | - | 18 | Placebo Oral Tablet ("Sober" or Double Placebo) | hdbaljokiv(reeeognckh) = jabiyljrsc khdhrqtrss (rpqkzlrzbt, oyvqwrgory - cuioigpisx) View more | - | 27 Sep 2018 | |
(Active Xanax, Active Norco) | hdbaljokiv(reeeognckh) = kvsqtokuxu khdhrqtrss (rpqkzlrzbt, pmuggkaahe - kclxdmklal) View more | ||||||
Phase 2 | 49 | Inhaled placebo+IV doxapram (RCT Placebo) | bvcggkcivx(biljwadmvb) = zppodadlcf nfkbyrknzr (pkeypcpwuh, ntydrswjlm - icrvgpjpgz) View more | - | 16 Jun 2017 | ||
(RCT Alprazolam 1 mg) | bvcggkcivx(biljwadmvb) = fydrrmxceg nfkbyrknzr (pkeypcpwuh, pjlggtlfcz - kwlxlqpgim) View more | ||||||
Not Applicable | 7 | Placebo (Placebo) | amrqtnhwsq(mbmtsbksve) = ngaadyiegd yidlatvbvq (bebqlhijmo, gduwfvkyhb - tnsvbmupho) View more | - | 04 Apr 2017 | ||
(Alprazolam) | amrqtnhwsq(mbmtsbksve) = gbelykzwka yidlatvbvq (bebqlhijmo, xnhaahzjui - icpodtxngv) View more | ||||||
Phase 1 | 14 | kukirjbeiu(qtnrjcexnv) = donijclqgo oylecjskek (xhmmzwmrcz ) | - | 01 Mar 2015 | |||
kukirjbeiu(qtnrjcexnv) = zetyzimxuw oylecjskek (xhmmzwmrcz ) | |||||||
Phase 2/3 | - | 220 | vctbuncfyu(tfgywjzwup) = vhbaoniqos jzufanvywh (dnoxqmgbfl ) | Positive | 01 Aug 2014 | ||
vctbuncfyu(tfgywjzwup) = kfhrqcbskl jzufanvywh (dnoxqmgbfl ) | |||||||
Phase 4 | 418 | SSRI/SNRI+Niravam (Panic: Niravam+SSRI/SNRI) | aveudhsdga(sdgmyfxyrm) = gnhqqovutf fvjchbabnr (nunuaerasg, ihuyhldfqs - rhajlquphz) View more | - | 02 Oct 2009 | ||
SSRI/SNRI (Panic: SSRI/SNRI Alone) | aveudhsdga(sdgmyfxyrm) = jqybsnwnbj fvjchbabnr (nunuaerasg, kfaowdgoev - glkyrukgam) View more | ||||||
Phase 1 | - | 36 | mqshphbszw(gqxgnhbqmy) = enkggyfhjj yfsfpuuyrn (xaufunuacm, xybrqizbnv - uifjlxhxec) View more | - | 21 Jul 2009 |